Fig. 2From: Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialRates of all gastrointestinal adverse events; of nausea, vomiting, and diarrhea; and use of gastrointestinal-directed concomitant medications over time in the QUAZAR AML-001 trialBack to article page